LITTLE FALLS, N.J. Cantel Medical Corp. announced today that its subsidiary, Minntech Corporation, has received expanded approval from the United States Environmental Protection Agency (EPA) for the use of its Minncare® Cold Sterilant in fogging applications.
Minncare® Cold Sterilant, in its liquid form, is widely used to disinfect ultrapure water production and distribution systems in critical applications such as kidney dialysis centers, pharmaceutical manufacturing and the micro-electronics industries.
Roy K Malkin, president and CEO of Minntech, noted: The expanded EPA approval covers applications of key concentrations and droplet sizes that will allow our U.S. customers to use Minncare® Cold Sterilant in a much wider range of fogging applications. Our experience and testing in Europe and Japan have shown that the use of Minncare® Cold Sterilant in a dry fog state at specific combinations of concentration and droplet size can provide significant benefits over aldehyde-based fogging systems. In particular, Minncare fogging applications in biotechnology and pharmaceutical manufacturing clean rooms are quite rapid and can minimize down time of manufacturing equipment.
He continued, Today, the contamination of surfaces with airborne pathogens has become an area of increasing concern, and we believe that the utilization of Minncare® Cold Sterilant, in its dry fog state, provides a safe and effective alternative for a variety of applications.
Cantel Medical Corp., a healthcare company, is a leading provider of infection prevention and control products, specialized medical device reprocessing systems, water treatment systems, sterilants, specialty packaging for shipping infectious and biological substances, diagnostic imaging and therapeutic medical equipment primarily focused on endoscopy, hollow fiber membrane filtration and separation technologies for medical and non-medical applications, and scientific instrumentation.
Source: Cantel Medical Corp.
